1. Home
  2. STVN vs RARE Comparison

STVN vs RARE Comparison

Compare STVN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

N/A

Current Price

$15.78

Market Cap

3.9B

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

N/A

Current Price

$16.03

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STVN
RARE
Founded
1949
2010
Country
Italy
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
1.6B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
STVN
RARE
Price
$15.78
$16.03
Analyst Decision
Buy
Buy
Analyst Count
13
21
Target Price
$19.46
★ $25.35
AVG Volume (30 Days)
1.1M
★ 3.3M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
★ 0.42%
N/A
EPS Growth
N/A
★ 7.31
EPS
★ N/A
N/A
Revenue
N/A
★ $673,000,000.00
Revenue This Year
$6.90
$12.70
Revenue Next Year
$2.38
$29.06
P/E Ratio
$27.15
★ N/A
Revenue Growth
N/A
★ 20.13
52 Week Low
$12.05
$12.73
52 Week High
$24.01
$39.89

Technical Indicators

Market Signals
Indicator
STVN
RARE
Relative Strength Index (RSI) 42.52 49.08
Support Level $13.12 $14.11
Resistance Level $17.19 $17.67
Average True Range (ATR) 1.10 0.90
MACD -0.15 0.03
Stochastic Oscillator 42.74 37.06

Price Performance

Historical Comparison
STVN
RARE

About STVN Stevanato Group S.p.A.

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: